Melatonin as a Promising Anti-Inflammatory Agent in an In Vivo Animal Model of Sepsis-Induced Rat Liver Damage
International Journal of Molecular Sciences · 29.12.2023 · 25 (1) · 455
DOI: 10.3390/ijms25010455 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 29.12.2023. Verfasst von Daniela Benedeto-Stojanov und 10 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, University of Niš, 18000 Niš, Serbia. Hauptthemen laut MEDLINE: Melatonin, Sepsis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministarstvo prosvete nauke i tehnološkog razvoja republike srbije, Ministry of Education, Science, and Technological Development of the Republic of Serbia.
Themen: Sepsis
Abstract (Originalsprache)
Melatonin (MLT), earlier described as an effective anti-inflammatory agent, could be a beneficial adjunctive drug for sepsis treatment. This study aimed to determine the effects of MLT application in lipopolysaccharide (LPS)-induced sepsis in Wistar rats by determining the levels of liver tissue pro-inflammatory cytokines (TNF-α, IL-6) and NF-κB as well as hematological parameters indicating the state of sepsis. Additionally, an immunohistological analysis of CD14 molecule expression was conducted. Our research demonstrated that treatment with MLT prevented an LPS-induced increase in pro-inflammatory cytokines TNF-α and IL-6 and NF-κB levels, and in the neutrophil to lymphocyte ratio (NLR). On the other hand, MLT prevented a decrease in the blood lymphocyte number induced by LPS administration. Also, treatment with MLT decreased the liver tissue expression of the CD14 molecule observed after sepsis induction. In summary, in rats with LPS-induced sepsis, MLT was shown to be a significant anti-inflammatory agent with the potential to change the liver’s immunological marker expression, thus ameliorating liver function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, University of Niš, 18000 Niš, Serbia.
- COVID Hospital Kruševac, University Clinical Centre of Niš, 37000 Kruševac, Serbia.
- Clinic of Gastroenterohepatology, University Clinical Centre of Niš, 18000 Niš, Serbia.
- General Hospital Leskovac, Department of General Surgery with Traumatology, 16000 Leskovac, Serbia.
- Faculty of Medicine, University of Priština, 38220 Kosovska Mitrovica, Serbia.
- Pediatrics Clinic, Clinical Centre Priština, 38205 Gracanica, Serbia.
ORCID-Profile: Andrija Rancić, Zoran P Marčetić, Milan Lazarević, Dušan Sokolović
Förderung
- Ministarstvo prosvete nauke i tehnološkog razvoja republike srbije
- Ministry of Education, Science, and Technological Development of the Republic of Serbia
Zitieren
APA
Benedeto-Stojanov, D., Ničković, V. P., Petrović, G., Rancić, A., Grgov, I., Nikolić, G. R., Marčetić, Z. P., Popović, M. R., Lazarević, M., Mitić, K. V., & Sokolović, D. (2023). Melatonin as a Promising Anti-Inflammatory Agent in an In Vivo Animal Model of Sepsis-Induced Rat Liver Damage. International Journal of Molecular Sciences, 25(1), 455. https://doi.org/10.3390/ijms25010455
Vancouver
Benedeto-Stojanov D, Ničković VP, Petrović G, Rancić A, Grgov I, Nikolić GR, et al. Melatonin as a Promising Anti-Inflammatory Agent in an In Vivo Animal Model of Sepsis-Induced Rat Liver Damage. International Journal of Molecular Sciences. 2023;25(1):455. doi:10.3390/ijms25010455
BibTeX
@article{BenedetoStojanov2023,
author = {Benedeto-Stojanov, Daniela and Ničković, Vanja P and Petrović, Gordana and Rancić, Andrija and Grgov, Ivan and Nikolić, Gordana R and Marčetić, Zoran P and Popović, Milica R and Lazarević, Milan and Mitić, Katarina V and Sokolović, Dušan},
title = {Melatonin as a Promising Anti-Inflammatory Agent in an In Vivo Animal Model of Sepsis-Induced Rat Liver Damage},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {25},
number = {1},
pages = {455},
doi = {10.3390/ijms25010455}
}
EUVIMED